Free Trial
→ You missed yesterday's deadline… (From Behind the Markets) (Ad)tc pixel
NASDAQ:VOGX

Vogenx Q3 2026 Earnings Results & Report

Vogenx logo
$19.58 +1.24 (+6.76%)
As of 02:44 PM Eastern

Vogenx beat analyst earnings expectations in its Q3 2026 results, released November 6, 2026. The company reported EPS of -$0.14 versus the -$0.15 consensus estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Vogenx EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.15
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Vogenx Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Vogenx's Q3 2026 Press ReleasePress Release
(8-K)
Vogenx's Q3 2026 Quarterly reportQuarterly report
(10-Q)

Vogenx Q3 2026 Earnings FAQ

Vogenx (NASDAQ:VOGX) reported earnings of -$0.14 per share for Q3 2026, beating the consensus estimate of -$0.15. The report was announced on Friday, November 6, 2026.

Vogenx Earnings Headlines

Vogenx, Inc.: Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia
October 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-10/69851689-vogenx-inc-vogenx-initiates-phase-2b-emerge-study-of-mizagliflozin-for-post-bariatric-hypoglycemia-200.htm
Vogenx Appoints Richard Gorman Chief Commercial Officer
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vogenx-appoints-richard-gorman-chief-130246010.html
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
November 10 at 1:00 AM  |  Behind the Markets (Ad)
VOGX Share News Today
October 8, 2026  |  uk.investing.comhttps://uk.investing.com/equities/vogenx-inc-news
Vogenx (VOGX) Stock Forecast & Price Target
September 6, 2026  |  investing.comhttps://www.investing.com/equities/vogenx-inc-consensus-estimates
WBB Securities initiates coverage of Vogenx (VOGX) with speculative buy rating
September 4, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/wbb-securities-initiates-coverage-of-vogenx-vogx-with-speculative-buy-rating/ar-AA2bzlqt
See More Vogenx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vogenx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vogenx and other key companies, straight to your email.

About Vogenx

Vogenx (NASDAQ:VOGX), Inc. is a biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. The company has historically concentrated on small-molecule drug candidates intended to address conditions in which existing treatment options may be limited.

Vogenx’s lead development program has included VGX-1027, an investigational anti-inflammatory compound studied for its potential to regulate abnormal immune responses. Research involving the candidate has focused on diseases associated with inflammation and immune-system dysfunction, although its development status and commercial availability may change over time.

The company’s activities have primarily involved pharmaceutical research and development rather than the marketing of an established portfolio of products. Publicly available information about Vogenx’s current operations, geographic reach and leadership is limited.

View Vogenx Profile
Earnings Tools